KEGG   Homo sapiens (human): 3560
Entry
3560              CDS       T01001                                 
Symbol
IL2RB, CD122, IL15RB, IMD63, P70-75
Name
(RefSeq) interleukin 2 receptor subunit beta
  KO
K05069  interleukin 2 receptor beta
Organism
hsa  Homo sapiens (human)
Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04061  Viral protein interaction with cytokine and cytokine receptor
hsa04144  Endocytosis
hsa04151  PI3K-Akt signaling pathway
hsa04630  JAK-STAT signaling pathway
hsa04658  Th1 and Th2 cell differentiation
hsa04659  Th17 cell differentiation
hsa05162  Measles
hsa05166  Human T-cell leukemia virus 1 infection
hsa05200  Pathways in cancer
hsa05202  Transcriptional misregulation in cancer
Network
nt06160  Human T-cell leukemia virus 1 (HTLV-1)
nt06162  Hepatitis B virus (HBV)
nt06164  Kaposi sarcoma-associated herpesvirus (KSHV)
nt06165  Epstein-Barr virus (EBV)
nt06219  JAK-STAT signaling (cancer)
nt06240  Transcription (cancer)
nt06263  Hepatocellular carcinoma
nt06266  Non-small cell lung cancer
nt06276  Chronic myeloid leukemia
nt06518  JAK-STAT signaling
  Element
N00053  Cytokine-Jak-STAT signaling pathway
N00137  EWSR1-WT1 fusion to transcriptional activation
N00491  HTLV-1 p12 to Jak-STAT signaling pathway
N01554  IL2 family to Jak-STAT signaling pathway
Disease
H02525  Disorders of innate immunity
Drug target
Aldesleukin: D00748<US>
Bempegaldesleukin: D11669
Celmoleukin: D02743
Rezpegaldesleukin: D12328
Teceleukin: D02749<JP>
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04630 JAK-STAT signaling pathway
    3560 (IL2RB)
   04151 PI3K-Akt signaling pathway
    3560 (IL2RB)
  09133 Signaling molecules and interaction
   04060 Cytokine-cytokine receptor interaction
    3560 (IL2RB)
   04061 Viral protein interaction with cytokine and cytokine receptor
    3560 (IL2RB)
 09140 Cellular Processes
  09141 Transport and catabolism
   04144 Endocytosis
    3560 (IL2RB)
 09150 Organismal Systems
  09151 Immune system
   04658 Th1 and Th2 cell differentiation
    3560 (IL2RB)
   04659 Th17 cell differentiation
    3560 (IL2RB)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    3560 (IL2RB)
   05202 Transcriptional misregulation in cancer
    3560 (IL2RB)
  09172 Infectious disease: viral
   05166 Human T-cell leukemia virus 1 infection
    3560 (IL2RB)
   05162 Measles
    3560 (IL2RB)
 09180 Brite Hierarchies
  09183 Protein families: signaling and cellular processes
   04050 Cytokine receptors [BR:hsa04050]
    3560 (IL2RB)
   04090 CD molecules [BR:hsa04090]
    3560 (IL2RB)
Cytokine receptors [BR:hsa04050]
 Interleukin receptor families
  IL2 receptor family
   3560 (IL2RB)
CD molecules [BR:hsa04090]
 Proteins
  3560 (IL2RB)
SSDB
Motif
Pfam: IL2RB_N1 fn3 Pur_ac_phosph_N IL6Ra-bind
Other DBs
NCBI-GeneID: 3560
NCBI-ProteinID: NP_000869
OMIM: 146710
HGNC: 6009
Ensembl: ENSG00000100385
UniProt: P14784
Structure
LinkDB
Position
22:complement(37125838..37175118)
AA seq 551 aa
MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ
VHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA
IQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE
APLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT
IPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV
QKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT
NQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT
FPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP
DLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ
ELQGQDPTHLV
NT seq 1656 nt   +upstreamnt  +downstreamnt
atggcggcccctgctctgtcctggcgtctgcccctcctcatcctcctcctgcccctggct
acctcttgggcatctgcagcggtgaatggcacttcccagttcacatgcttctacaactcg
agagccaacatctcctgtgtctggagccaagatggggctctgcaggacacttcctgccaa
gtccatgcctggccggacagacggcggtggaaccaaacctgtgagctgctccccgtgagt
caagcatcctgggcctgcaacctgatcctcggagccccagattctcagaaactgaccaca
gttgacatcgtcaccctgagggtgctgtgccgtgagggggtgcgatggagggtgatggcc
atccaggacttcaagccctttgagaaccttcgcctgatggcccccatctccctccaagtt
gtccacgtggagacccacagatgcaacataagctgggaaatctcccaagcctcccactac
tttgaaagacacctggagttcgaggcccggacgctgtccccaggccacacctgggaggag
gcccccctgctgactctcaagcagaagcaggaatggatctgcctggagacgctcacccca
gacacccagtatgagtttcaggtgcgggtcaagcctctgcaaggcgagttcacgacctgg
agcccctggagccagcccctggccttcaggacaaagcctgcagcccttgggaaggacacc
attccgtggctcggccacctcctcgtgggcctcagcggggcttttggcttcatcatctta
gtgtacttgctgatcaactgcaggaacaccgggccatggctgaagaaggtcctgaagtgt
aacaccccagacccctcgaagttcttttcccagctgagctcagagcatggaggagacgtc
cagaagtggctctcttcgcccttcccctcatcgtccttcagccctggcggcctggcacct
gagatctcgccactagaagtgctggagagggacaaggtgacgcagctgctcctgcagcag
gacaaggtgcctgagcccgcatccttaagcagcaaccactcgctgaccagctgcttcacc
aaccagggttacttcttcttccacctcccggatgccttggagatagaggcctgccaggtg
tactttacttacgacccctactcagaggaagaccctgatgagggtgtggccggggcaccc
acagggtcttccccccaacccctgcagcctctgtcaggggaggacgacgcctactgcacc
ttcccctccagggatgacctgctgctcttctcccccagtctcctcggtggccccagcccc
ccaagcactgcccctgggggcagtggggccggtgaagagaggatgcccccttctttgcaa
gaaagagtccccagagactgggacccccagcccctggggcctcccaccccaggagtccca
gacctggtggattttcagccaccccctgagctggtgctgcgagaggctggggaggaggtc
cctgacgctggccccagggagggagtcagtttcccctggtccaggcctcctgggcagggg
gagttcagggcccttaatgctcgcctgcccctgaacactgatgcctacttgtccctccaa
gaactccagggtcaggacccaactcacttggtgtag

KEGG   DISEASE: Disorders of innate immunity
Entry
H02525                      Disease                                
Name
Disorders of innate immunity
  Subgroup
WHIM syndrome [DS:H00097]
Chronic granulomatous disease [DS:H00098]
Leukocyte adhesion deficiency [DS:H00099]
Classic complement pathway component defects [DS:H00102]
Late complement pathway defects [DS:H00103]
Alternative complement pathway component defects [DS:H00104]
Mannose-binding lectin pathway component defects [DS:H00105]
Complement regulatory protein defects [DS:H00106]
Other phagocyte defects [DS:H00101]
IFN-gamma/IL-12 axis [DS:H00089]
Defects of toll-like receptor signaling [DS:H00096]
NK cell defects [DS:H00090]
  Supergrp
Primary immunodeficiency disease [DS:H01725]
Description
Innate immune responses represent the first line of defense against potentially invading organisms. Disorders of innate immunity (e.g. phagocyte and complement disorders) delay the induction of the immune response and may worsen outcomes of infection.
Category
Immune system disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 04 Diseases of the immune system
  Primary immunodeficiencies
   4A00  Primary immunodeficiencies due to disorders of innate immunity
    H02525  Disorders of innate immunity
Pathway-based classification of diseases [BR:br08402]
 Replication and repair
  nt06509  DNA replication
   H02525  Disorders of innate immunity
 Signal transduction
  nt06518  JAK-STAT signaling
   H02525  Disorders of innate immunity
  nt06516  TNF signaling
   H02525  Disorders of innate immunity
 Cellular process
  nt06527  Necroptosis
   H02525  Disorders of innate immunity
 Immune system
  nt06519  RLR signaling
   H02525  Disorders of innate immunity
Pathway
hsa04630  JAK-STAT signaling pathway
hsa04668  TNF signaling pathway
hsa04622  RIG-I-like receptor signaling pathway
hsa04217  Necroptosis
Network
nt06509 DNA replication
nt06516 TNF signaling
nt06518 JAK-STAT signaling
nt06519 RLR signaling
nt06527 Necroptosis
Gene
(IMD44) STAT2 [HSA:6773] [KO:K11221]
(IMD45) IFNAR2 [HSA:3455] [KO:K05131]
(IMD57) RIPK1 [HSA:8737] [KO:K02861]
(IMD63) IL2RB [HSA:3560] [KO:K05069]
(IMD65) IRF9 [HSA:10379] [KO:K04693]
(IMD77) MPEG1 [HSA:219972] [KO:K26547]
(IMD80) MCM10 [HSA:55388] [KO:K10736]
(IMD90) FADD [HSA:8772] [KO:K02373]
(IMD91) ZNFX1 [HSA:57169] [KO:K27391]
(IMD95) IFIH1 [HSA:64135] [KO:K12647]
(IMD103) CARD9 [HSA:64170] [KO:K12794]
(IMD106) IFNAR1 [HSA:3454] [KO:K05130]
(IMD115) RNF31 [HSA:55072] [KO:K11974]
(IMD117) IRF1 [HSA:3659] [KO:K09444]
(IMD127) TNF [HSA:7124] [KO:K03156]
Other DBs
ICD-11: 4A00
MeSH: D000081207
OMIM: 616636 616669 618108 618495 618648 619223 619313 613759 619644 619773 212050 619935 620632 620668 620977
Reference
  Authors
McCusker C, Warrington R
  Title
Primary immunodeficiency.
  Journal
Allergy Asthma Clin Immunol 7 Suppl 1:S11 (2011)
DOI:10.1186/1710-1492-7-S1-S11
Reference
PMID:23391734 (IMD44)
  Authors
Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M, McGovern N, Cant AJ, Hackett SJ, Ghazal P, Morgan NV, Randall RE
  Title
STAT2 deficiency and susceptibility to viral illness in humans.
  Journal
Proc Natl Acad Sci U S A 110:3053-8 (2013)
DOI:10.1073/pnas.1220098110
Reference
PMID:26424569 (IMD45)
  Authors
Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, Butler KM, Morfopoulou S, Brown JR, Hubank M, Connell J, Gavin PJ, McMahon C, Dempsey E, Lynch NE, Jacques TS, Valappil M, Cant AJ, Breuer J, Engelhardt KR, Randall RE, Hambleton S
  Title
Human IFNAR2 deficiency: Lessons for antiviral immunity.
  Journal
Sci Transl Med 7:307ra154 (2015)
DOI:10.1126/scitranslmed.aac4227
Reference
PMID:30026316 (IMD57)
  Authors
Cuchet-Lourenco D, Eletto D, Wu C, Plagnol V, Papapietro O, Curtis J, Ceron-Gutierrez L, Bacon CM, Hackett S, Alsaleem B, Maes M, Gaspar M, Alisaac A, Goss E, AlIdrissi E, Siegmund D, Wajant H, Kumararatne D, AlZahrani MS, Arkwright PD, Abinun M, Doffinger R, Nejentsev S
  Title
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.
  Journal
Science 361:810-813 (2018)
DOI:10.1126/science.aar2641
Reference
PMID:31040184 (IMD63)
  Authors
Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, Lundquist K, Nguyen T, Ogolla S, Black J, Galambos C, Gumbart JC, Dawany N, Kelsen JR, de Zoeten EF, Quinones R, Eissa H, Verneris MR, Sullivan KE, Rochford R, Blish CA, Kedl RM, Dutmer CM, Hsieh EWY
  Title
A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation.
  Journal
J Exp Med 216:1255-1267 (2019)
DOI:10.1084/jem.20182015
Reference
PMID:30826365 (IMD65)
  Authors
Bravo Garcia-Morato M, Calvo Apalategi A, Bravo-Gallego LY, Blazquez Moreno A, Simon-Fuentes M, Garmendia JV, Mendez Echevarria A, Del Rosal Rabes T, Dominguez-Soto A, Lopez-Granados E, Reyburn HT, Rodriguez Pena R
  Title
Impaired control of multiple viral infections in a family with complete IRF9 deficiency.
  Journal
J Allergy Clin Immunol 144:309-312.e10 (2019)
DOI:10.1016/j.jaci.2019.02.019
Reference
PMID:33224153 (IMD77)
  Authors
Merselis LC, Jiang SY, Nelson SF, Lee H, Prabaker KK, Baker JL, Munson GP, Butte MJ
  Title
MPEG1/Perforin-2 Haploinsufficiency Associated Polymicrobial Skin Infections and Considerations for Interferon-gamma Therapy.
  Journal
Front Immunol 11:601584 (2020)
DOI:10.3389/fimmu.2020.601584
Reference
PMID:32865517 (IMD80)
  Authors
Mace EM, Paust S, Conte MI, Baxley RM, Schmit MM, Patil SL, Guilz NC, Mukherjee M, Pezzi AE, Chmielowiec J, Tatineni S, Chinn IK, Akdemir ZC, Jhangiani SN, Muzny DM, Stray-Pedersen A, Bradley RE, Moody M, Connor PP, Heaps AG, Steward C, Banerjee PP, Gibbs RA, Borowiak M, Lupski JR, Jolles S, Bielinsky AK, Orange JS
  Title
Human NK cell deficiency as a result of biallelic mutations in MCM10.
  Journal
J Clin Invest 130:5272-5286 (2020)
DOI:10.1172/JCI134966
Reference
PMID:21109225 (IMD90)
  Authors
Bolze A, Byun M, McDonald D, Morgan NV, Abhyankar A, Premkumar L, Puel A, Bacon CM, Rieux-Laucat F, Pang K, Britland A, Abel L, Cant A, Maher ER, Riedl SJ, Hambleton S, Casanova JL
  Title
Whole-exome-sequencing-based discovery of human FADD deficiency.
  Journal
Am J Hum Genet 87:873-81 (2010)
DOI:10.1016/j.ajhg.2010.10.028
Reference
PMID:33876776 (IMD91)
  Authors
Le Voyer T, Neehus AL, Yang R, Ogishi M, Rosain J, Alroqi F, Alshalan M, Blumental S, Al Ali F, Khan T, Ata M, Rozen L, Demulder A, Bastard P, Gruber C, Roynard M, Seeleuthener Y, Rapaport F, Bigio B, Chrabieh M, Sng D, Berteloot L, Boddaert N, Rozenberg F, Al-Muhsen S, Bertoli-Avella A, Abel L, Bogunovic D, Marr N, Mansouri D, Al Mutairi F, Beziat V, Weil D, Mahdaviani SA, Ferster A, Zhang SY, Reversade B, Boisson-Dupuis S, Casanova JL, Bustamante J
  Title
Inherited deficiency of stress granule ZNFX1 in patients with monocytosis and mycobacterial disease.
  Journal
Proc Natl Acad Sci U S A 118:2102804118 (2021)
DOI:10.1073/pnas.2102804118
Reference
PMID:28606988 (IMD95)
  Authors
Lamborn IT, Jing H, Zhang Y, Drutman SB, Abbott JK, Munir S, Bade S, Murdock HM, Santos CP, Brock LG, Masutani E, Fordjour EY, McElwee JJ, Hughes JD, Nichols DP, Belkadi A, Oler AJ, Happel CS, Matthews HF, Abel L, Collins PL, Subbarao K, Gelfand EW, Ciancanelli MJ, Casanova JL, Su HC
  Title
Recurrent rhinovirus infections in a child with inherited MDA5 deficiency.
  Journal
J Exp Med 214:1949-1972 (2017)
DOI:10.1084/jem.20161759
Reference
PMID:19864672 (IMD103)
  Authors
Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, Pfeifer D, Veelken H, Warnatz K, Tahami F, Jamal S, Manguiat A, Rezaei N, Amirzargar AA, Plebani A, Hannesschlager N, Gross O, Ruland J, Grimbacher B
  Title
A homozygous CARD9 mutation in a family with susceptibility to fungal infections.
  Journal
N Engl J Med 361:1727-35 (2009)
DOI:10.1056/NEJMoa0810719
Reference
PMID:35091979 (IMD106)
  Authors
Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L, Aranda-Guillen M, Sardh F, Zuo F, Zhang P, Marcotte H, Marr N, Khan T, Ata M, Al-Ali F, Pescarmona R, Belot A, Beziat V, Zhang Q, Casanova JL, Kampe O, Zhang SY, Hammarstrom L, Pan-Hammarstrom Q
  Title
Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome.
  Journal
J Clin Immunol 42:471-483 (2022)
DOI:10.1007/s10875-022-01215-7
Reference
PMID:26008899 (IMD115)
  Authors
Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M, Lidov HG, Hopkins G, Du L, Belkadi A, Chrabieh M, Itan Y, Picard C, Fournet JC, Eibel H, Tsitsikov E, Pai SY, Abel L, Al-Herz W, Casanova JL, Israel A, Notarangelo LD
  Title
Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia.
  Journal
J Exp Med 212:939-51 (2015)
DOI:10.1084/jem.20141130
Reference
PMID:36736301 (IMD117)
  Authors
Rosain J, Neehus AL, Manry J, Yang R, Le Pen J, Daher W, Liu Z, Chan YH, Tahuil N, Turel O, Bourgey M, Ogishi M, Doisne JM, Izquierdo HM, Shirasaki T, Le Voyer T, Guerin A, Bastard P, Moncada-Velez M, Han JE, Khan T, Rapaport F, Hong SH, Cheung A, Haake K, Mindt BC, Perez L, Philippot Q, Lee D, Zhang P, Rinchai D, Al Ali F, Ahmad Ata MM, Rahman M, Peel JN, Heissel S, Molina H, Kendir-Demirkol Y, Bailey R, Zhao S, Bohlen J, Mancini M, Seeleuthner Y, Roelens M, Lorenzo L, Soudee C, Paz MEJ, Gonzalez ML, Jeljeli M, Soulier J, Romana S, L'Honneur AS, Materna M, Martinez-Barricarte R, Pochon M, Oleaga-Quintas C, Michev A, Migaud M, Levy R, Alyanakian MA, Rozenberg F, Croft CA, Vogt G, Emile JF, Kremer L, Ma CS, Fritz JH, Lemon SM, Spaan AN, Manel N, Abel L, MacDonald MR, Boisson-Dupuis S, Marr N, Tangye SG, Di Santo JP, Zhang Q, Zhang SY, Rice CM, Beziat V, Lachmann N, Langlais D, Casanova JL, Gros P, Bustamante J
  Title
Human IRF1 governs macrophagic IFN-gamma immunity to mycobacteria.
  Journal
Cell 186:621-645.e33 (2023)
DOI:10.1016/j.cell.2022.12.038
LinkDB

» Japanese version

KEGG   DRUG: Aldesleukin
Entry
D00748                      Drug                                   
Name
Aldesleukin (USAN/INN);
Interleukin-2;
Proleukin (TN)
Product
Formula
C690H1115N177O203S6
Exact mass
15321.0691
Mol weight
15330.70
Sequence
Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu
Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn
Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys
Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro
Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg
Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys
Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr
Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile
Ser Thr Leu Thr
  Type
Peptide
Remark
Same as: C07903
ATC code: L03AC01
Product: D00748<US>
Efficacy
Antineoplastic, Immunostimulant, Biological response modifier
  Disease
Renal cell carcinoma [DS:H00021]
Melanoma [DS:H00038]
Comment
human recombinant interleukin-2 product
Target
IL2RA (CD25) [HSA:3559] [KO:K05068]
IL2RB (CD122) [HSA:3560] [KO:K05069]
IL2RG (CD132) [HSA:3561] [KO:K05070]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
hsa05200  Pathways in cancer
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L03 IMMUNOSTIMULANTS
   L03A IMMUNOSTIMULANTS
    L03AC Interleukins
     L03AC01 Aldesleukin
      D00748  Aldesleukin (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antineoplastics, Other
   Antineoplastics, Miscellaneous
    Aldesleukin
     D00748  Aldesleukin (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RA (CD25)
     D00748  Aldesleukin (USAN/INN) <US>
    IL2RB (CD122)
     D00748  Aldesleukin (USAN/INN) <US>
    IL2RG (CD132)
     D00748  Aldesleukin (USAN/INN) <US>
Other DBs
CAS: 110942-02-4
PubChem: 7847813
LinkDB

» Japanese version   » Back

KEGG   DRUG: Celmoleukin
Entry
D02743                      Drug                                   
Name
Celmoleukin (genetical recombination) (JP18);
Celmoleukin (INN);
Celeuk (TN)
Formula
C693H1118N178O203S7
Exact mass
15406.0677
Mol weight
15415.83
Efficacy
Antineoplastic, Immunostimulant, Biological response modifier
Comment
recombinant interleukin 2 [HSA:3558] [KO:K05429]
Target
IL2RA (CD25) [HSA:3559] [KO:K05068]
IL2RB (CD122) [HSA:3560] [KO:K05069]
IL2RG (CD132) [HSA:3561] [KO:K05070]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RA (CD25)
     D02743  Celmoleukin (genetical recombination) (JP18)
    IL2RB (CD122)
     D02743  Celmoleukin (genetical recombination) (JP18)
    IL2RG (CD132)
     D02743  Celmoleukin (genetical recombination) (JP18)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D02743  Celmoleukin (genetical recombination)
Other DBs
CAS: 94218-72-1
PubChem: 17396906
LinkDB

» Japanese version   » Back

KEGG   DRUG: Teceleukin
Entry
D02749                      Drug                                   
Name
Teceleukin (USAN);
Teceleukin (genetical recombination) (JP18);
Imunace (TN)
Formula
C698H1127N179O204S8
Exact mass
15537.1082
Mol weight
15547.03
Sequence
MAPTSSSTKK TQLQLEHLLL DLQMILNGIN NYKNPKLTRM LTFKFYMPKK ATELKHLQCL
EEELKPLEEV LNLAQSKNFH LRPRDLISNI NVIVLELKGS ETTFMCEYAD ETATIVEFLN
RWITFCQSII STLT (Disulfid bridge: 59-106)
  Type
Peptide
Remark
Therapeutic category: 6399
Product: D02749<JP>
Efficacy
Antineoplastic, Immunostimulant, Biological response modifier
Comment
recombinant interleukin 2 [HSA:3558] [KO:K05429]
Target
IL2RA (CD25) [HSA:3559] [KO:K05068]
IL2RB (CD122) [HSA:3560] [KO:K05069]
IL2RG (CD132) [HSA:3561] [KO:K05070]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D02749  Teceleukin (USAN); Teceleukin (genetical recombination) (JP18)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RA (CD25)
     D02749  Teceleukin (USAN) <JP>
    IL2RB (CD122)
     D02749  Teceleukin (USAN) <JP>
    IL2RG (CD132)
     D02749  Teceleukin (USAN) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D02749  Teceleukin (genetical recombination)
  D02749  Teceleukin for injection (genetical recombination)
Other DBs
CAS: 136279-32-8
PubChem: 47205821
LinkDB

» Japanese version   » Back

KEGG   DRUG: Bempegaldesleukin
Entry
D11669                      Drug                                   
Name
Bempegaldesleukin (USAN/INN)
Formula
C690H1113N177O203S6. (C19H16N2O4(C2H4O)2n)6
Sequence
PTSSSTKKTQ LQLEHLLLDL QMILNGINNY KNPKLTRMLT FKFYMPKKAT ELKHLQCLEE
ELKPLEEVLN LAQSKNFHLR PRDLISNINV IVLELKGSET TFMCEYADET ATIVEFLNRW
ITFSQSIIST LT
  Type
Peptide
Efficacy
Antineoplastic
Comment
for cancer immunotherapy
peglyated interleukin 2
Target
IL2RB (CD122) [HSA:3560] [KO:K05069]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RB (CD122)
     D11669  Bempegaldesleukin (USAN/INN)
Other DBs
CAS: 1939126-74-5
PubChem: 405226536
LinkDB

» Japanese version   » Back

KEGG   DRUG: Rezpegaldesleukin
Entry
D12328                      Drug                                   
Name
Rezpegaldesleukin (USAN)
Sequence
PTSSSTKKTQ LQLEHLLLDL QMILNGINNY KNPKLTRMLT FKFYMPKKAT ELKHLQCLEE
ELKPLEEVLN LAQSKNFHLR PRDLISNINV IVLELKGSET TFMCEYADET ATIVEFLNRW
ITFSQSIIST LT
(Disulfide bridge: 57-104)
  Type
Peptide
Efficacy
Autoimmune disease treatment
Comment
human recombinant interleukin-2 product
Treatment of autoimmune diseases
Target
IL2RA (CD25) [HSA:3559] [KO:K05068]
IL2RB (CD122) [HSA:3560] [KO:K05069]
IL2RG (CD132) [HSA:3561] [KO:K05070]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RA (CD25)
     D12328  Rezpegaldesleukin (USAN)
    IL2RB (CD122)
     D12328  Rezpegaldesleukin (USAN)
    IL2RG (CD132)
     D12328  Rezpegaldesleukin (USAN)
Other DBs
CAS: 2641686-76-0
PubChem: 497620741
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system